TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 791329

Group type: EXPERIMENTAL
Intervention: labetalol 400 mg/d
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: labetalol 800 mg/d
Number of subjects: 30
Study: 30953546

Group type: EXPERIMENTAL
Intervention: Mastery learning and deliberate practice (ML + DP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Self-guided practice
Number of subjects: 160
Study: 27444848

Group type: EXPERIMENTAL
Intervention: Total Knee Arthroplasty (TKA)
Number of subjects: 2080
Study: 25590939

Group type: EXPERIMENTAL
Intervention: Fotonovela Condition (FNC)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Usual Information Condition (UIC)
Number of subjects: 110
Study: 22882879

Group type: EXPERIMENTAL
Intervention: Listening to a radio-broadcast while driving in high-complexity traffic
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Listening to a radio-broadcast while driving in low-complexity traffic
Number of subjects: 46

Group type: COMPARATOR
Intervention: Driving in silence (Control group)
Number of subjects: 46
Study: 20557973

Group type: EXPERIMENTAL
Intervention: Repressive coping style (n=30)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Low-anxious coping style (n=25)
Number of subjects: 107

Group type: COMPARATOR
Intervention: High-anxious coping style (n=31)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Defensive high-anxious coping style (n=21)
Number of subjects: 107
Study: 19597668

Group type: EXPERIMENTAL
Intervention: Auditory stimuli (music and voice message)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No auditory stimuli (Control Group)
Number of subjects: 30
Study: 17470884

Group type: EXPERIMENTAL
Intervention: Celecoxib (400 mg x day(‐1) po, followed by 200 mg po bid for three days)
Number of subjects: 80
Study: 15305252

Group type: EXPERIMENTAL
Intervention: Axillary block (A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Humeral block (H)
Number of subjects: 80
Study: 11668227

Group type: EXPERIMENTAL
Intervention: Open Appendectomy (OA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Laparoscopic Appendectomy (LA)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Needlescopic Appendectomy (nLA)
Number of subjects: 75
Study: 9667264

Group type: COMPARATOR
Intervention: Cisplatin 100 mg/m2 every 4 weeks
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m2 every 4 weeks and vinorelbine 25 mg/m2 weekly
Number of subjects: 432
Study: 8205778

Group type: EXPERIMENTAL
Intervention: Fluoride-containing amalgam
Number of subjects: 415

Group type: COMPARATOR
Intervention: Conventional amalgam
Number of subjects: 415
Study: 2645420

Group type: EXPERIMENTAL
Intervention: Intracorporeal papaverine (30 mg. per ml.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intracorporeal prostaglandin E1 (10 mcg. per ml.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 15

Group type: COMPARATOR
Intervention: Intracorporeal prostaglandin E1
Number of subjects: 15
Study: 31043808

Group type: EXPERIMENTAL
Intervention: Generic erlotinib ($1460.25 per 30 days)
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: Generic cetuximab ($275.80 per 100 mg)
Number of subjects: 1979

Group type: EXPERIMENTAL
Intervention: Generic cetuximab at reduced costs ($129.39 and $63.51)
Number of subjects: 1979
Study: 28253845

Group type: EXPERIMENTAL
Intervention: Multimodal therapy (MT) consisting of sleep education/restriction, psycho-education, eurythmy- and painting-therapy
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Combined therapy (CT) consisting of multimodal therapy (MT) plus aerobic training (AT)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Standard aerobic treatment (AT)
Number of subjects: 126
Study: 26188537

Group type: EXPERIMENTAL
Intervention: Lactobacillus casei Shirota (LcS) 6.5 × 10(9) CFU, 3 times daily for 12 weeks
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard therapy (no LcS)
Number of subjects: 30
Study: 23429924

Group type: EXPERIMENTAL
Intervention: Practice-based collaborative care
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Telemedicine-based collaborative care
Number of subjects: 364
Study: 22026403

Group type: EXPERIMENTAL
Intervention: Dietary and Lifestyle Advice Group
Number of subjects: 2180

Group type: COMPARATOR
Intervention: Standard Care Group
Number of subjects: 2180
Study: 19060419

Group type: EXPERIMENTAL
Intervention: Rhythm control
Number of subjects: 823

Group type: COMPARATOR
Intervention: Rate control
Number of subjects: 823
Study: 12972387

Group type: EXPERIMENTAL
Intervention: 5520 cGy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 5940 cGy
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 6375 cGy
Number of subjects: 67
Study: 10189455

Group type: EXPERIMENTAL
Intervention: Single-dose breath-hold gadolinium-enhanced MR angiography with 20 mL of gadopentetate dimeglumine (average dose, 0.11 mmol/kg)
Number of subjects: 60
Study: 7785485

Group type: EXPERIMENTAL
Intervention: smoking cessation plus exercise
Number of subjects: 20

Group type: COMPARATOR
Intervention: smoking cessation with frequency contact control
Number of subjects: 20
Study: 2080949

Group type: EXPERIMENTAL
Intervention: Intravenous calcium (9 mmol Calcium-Sandoz)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 396055

Group type: EXPERIMENTAL
Intervention: Praziquantel 3 x 20 mg/kg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Praziquantel 1 x 20 mg/kg and 2 x 20 mg/kg
Number of subjects: 51
Study: 31226123

Group type: EXPERIMENTAL
Intervention: Family planning voucher
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control (standard of care)
Number of subjects: 173
Study: 28001151

Group type: EXPERIMENTAL
Intervention: 5 g per day of DSG for 14 days
Number of subjects: 203

Group type: COMPARATOR
Intervention: 5 g per day of DSG for 30 days
Number of subjects: 203

Group type: COMPARATOR
Intervention: 5 g per day of placebo for 30 days
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 5 g per day of DSG for both studies
Number of subjects: 203
Study: 25648211

Group type: EXPERIMENTAL
Intervention: Soy isoflavones supplementation (33 g in the form of biscuits containing approximately 54 mg isoflavones for 8 weeks)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Soy isoflavones supplementation
Number of subjects: 61
Study: 23206316

Group type: EXPERIMENTAL
Intervention: Early mobilisation (Group A)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Early mobilisation plus breathing exercises (Group B)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Delayed mobilisation plus breathing exercises (Group C)
Number of subjects: 86
Study: 21112195

Group type: EXPERIMENTAL
Intervention: 0.8% mouth rinse
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: 1.4% gel
Number of subjects: 37

Group type: COMPARATOR
Intervention: Thy-Car mixture (control)
Number of subjects: 37
Study: 19679843

Group type: EXPERIMENTAL
Intervention: Endothelin-receptor antagonists (ETRAs)
Number of subjects: 867
Study: 17885991

Group type: EXPERIMENTAL
Intervention: Medium difficulty details mixed with hard details
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium difficulty details presented in blocked format preceded by a block of hard details
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informing participants of the relative difficulty of the upcoming block of details
Number of subjects: 0
Study: 15329425

Group type: EXPERIMENTAL
Intervention: Fluconazole (150 mg) weekly for six months
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo weekly for six months
Number of subjects: 387
Study: 11158796

Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 108

Group type: COMPARATOR
Intervention: Unoprostone 0.12% twice daily
Number of subjects: 108
Study: 9500800

Group type: EXPERIMENTAL
Intervention: Information (N=61)
Number of subjects: 115

Group type: COMPARATOR
Intervention: No information (N=54)
Number of subjects: 115
Study: 7826846

Group type: EXPERIMENTAL
Intervention: Etoposide (VP‐16) only in 50 patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: VP‐16 and other drugs with leukemogenic effect in 17 patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Only drugs with leukemogenic effect in 6 patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Other drugs in 35 patients
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Surgery only in 31 patients
Number of subjects: 139
Study: 30595329

Group type: EXPERIMENTAL
Intervention: Carvedilol 6.25 mg/day
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Carvedilol 12.5 mg/day
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg/day
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Carvedilol (all doses combined)
Number of subjects: 116
Study: 29917338

Group type: EXPERIMENTAL
Intervention: Continuous veno-venous hemofiltration (CVVH)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 74
Study: 24056161

Group type: EXPERIMENTAL
Intervention: Direct lateral approach
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Anterolateral approach
Number of subjects: 35

Group type: COMPARATOR
Intervention: All approaches
Number of subjects: 35
Study: 22397653

Group type: EXPERIMENTAL
Intervention: Pasireotide 600 μg twice daily
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Pasireotide 900 μg twice daily
Number of subjects: 162

Group type: EXPERIMENTAL
Intervention: Pasireotide (both doses)
Number of subjects: 162
Study: 20064692

Group type: EXPERIMENTAL
Intervention: Pentoxifylline (PTF) 1 mg ml(‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 18
Study: 19368505

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7) given 3 months after transplantation
Number of subjects: 158

Group type: COMPARATOR
Intervention: 7-valent pneumococcal conjugate vaccine (PCV7) given 9 months after transplantation
Number of subjects: 158
Study: 16418785

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN), 5-10 mg/day
Number of subjects: 6186

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 6186

Group type: EXPERIMENTAL
Intervention: Alendronate (ALN)
Number of subjects: 6186
Study: 15288321

Group type: EXPERIMENTAL
Intervention: Azithromycin (4.0 g total over 4 weeks, 1000 mg weekly)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Doxycycline (100 mg b.i.d. for 28 days)
Number of subjects: 125
Study: 11340962

Group type: EXPERIMENTAL
Intervention: Research methods and ethical standards in studies involving persons with mental retardation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informed consent and surrogate decision-making
Number of subjects: 0
Study: 9240875

Group type: EXPERIMENTAL
Intervention: Platelet tritiated imipramine (3H‐IMI) binding sites in coeliac disease patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 20
Study: 8482456

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate (20 mg three times a day, n = 57)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Propranolol (up to maximum tolerated dose, n = 61)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Isosorbide-5-mononitrate
Number of subjects: 118

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 118
Study: 2446058

Group type: EXPERIMENTAL
Intervention: Ketanserin (20 or 40 mg doses twice daily)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ketanserin + Atenolol (100 mg/day)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ketanserin + Hydrochlorothiazide (50 mg/day) + Amiloride (5 mg/day)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 124
Study: 29304837

Group type: EXPERIMENTAL
Intervention: OptiBIRTH intervention
Number of subjects: 0
Study: 27865174

Group type: EXPERIMENTAL
Intervention: cART+48 weeks of MVC (LT-MVC)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: cART+8 weeks of MVC (ST-MVC)
Number of subjects: 29

Group type: COMPARATOR
Intervention: cART-only (control group)
Number of subjects: 29
Study: 24252173

Group type: EXPERIMENTAL
Intervention: Sleep extension group (gradual sleep extension by advancing bedtimes in the evening and receiving sleep hygiene advice)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 55
Study: 22156663

Group type: EXPERIMENTAL
Intervention: Admira Flow
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Grandio Flow
Number of subjects: 35

Group type: COMPARATOR
Intervention: Fissurit F
Number of subjects: 35
Study: 20728065

Group type: EXPERIMENTAL
Intervention: Combined abbreviated progressive relaxation technique (APRT) and guided imagery (GI) intervention
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 19
Study: 18278830

Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Pregabalin 450 mg/day
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 748

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: Pregabalin (all doses)
Number of subjects: 748
Study: 15963092

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg once daily
Number of subjects: 371

Group type: COMPARATOR
Intervention: Interferon‐alfa plus cytarabine
Number of subjects: 371
Study: 12906966

Group type: EXPERIMENTAL
Intervention: i.v.+s.c. enoxaparin treatment
Number of subjects: 25

Group type: COMPARATOR
Intervention: s.c. alone enoxaparin treatment
Number of subjects: 25
Study: 10470389

Group type: EXPERIMENTAL
Intervention: Sevoflurane-remifentanil (Group SR)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fentanyl-etomidate (Group FE)
Number of subjects: 40
Study: 8735046

Group type: EXPERIMENTAL
Intervention: Helium insufflation
Number of subjects: 16

Group type: COMPARATOR
Intervention: CO2 insufflation
Number of subjects: 16
Study: 1817627

Group type: EXPERIMENTAL
Intervention: Incremental spinal anaesthesia using a 32-gauge catheter with 0.5% plain bupivacaine
Number of subjects: 43

Group type: COMPARATOR
Intervention: Extradural anaesthesia with pH-adjusted 2% lignocaine with 1/200,000 adrenaline
Number of subjects: 43
Study: 7066128

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 7.5 mg ml‐1 administered in sitting position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 5 mg ml‐1 administered in horizontal position
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 7.5 mg ml‐1 in horizontal posture
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isobaric bupivacaine 5 mg ml‐1 in horizontal posture
Number of subjects: 40
Study: 31625497

Group type: EXPERIMENTAL
Intervention: Korean version of the metacognitive training (MCT) program, 18 sessions, 60 min per session, over 14 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 59
Study: 30260724

Group type: EXPERIMENTAL
Intervention: 5 mL of 0.5% levobupivacaine applied at incision sites + 10 mL 0.5% levobupivacaine injected intraperitoneally and at trocar sites
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 5 mL of 0.5% ropivacaine at incision sites + 10 mL 0.5% ropivacaine injected intraperitoneally and at trocar sites
Number of subjects: 120

Group type: COMPARATOR
Intervention: No peritoneal or local administration of local anesthetics (Control Group 1)
Number of subjects: 120
Study: 27165179

Group type: EXPERIMENTAL
Intervention: CZP+MTX
Number of subjects: 879

Group type: COMPARATOR
Intervention: PBO+MTX
Number of subjects: 879
Study: 25331992

Group type: EXPERIMENTAL
Intervention: Brief intervention for indicated prevention of depression
Number of subjects: 173

Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Good complier caregivers
Number of subjects: 173
Study: 23291916

Group type: EXPERIMENTAL
Intervention: Nd:YAG laser (settings: 6 W, 60 mJ/pulse, and 100 Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scalpel technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 0
Study: 22449648

Group type: EXPERIMENTAL
Intervention: Transformational leadership
Number of subjects: 140

Group type: COMPARATOR
Intervention: Leader-member exchange
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: EBPI (evidence-based practice implementation)
Number of subjects: 140

Group type: COMPARATOR
Intervention: SAU (services as usual)
Number of subjects: 140
Study: 19541954

Group type: EXPERIMENTAL
Intervention: XBD173
Number of subjects: 0

Group type: COMPARATOR
Intervention: Benzodiazepines
Number of subjects: 0
Study: 17560989

Group type: EXPERIMENTAL
Intervention: Surgical therapy for cutaneous melanoma
Number of subjects: 0
Study: 15729204

Group type: EXPERIMENTAL
Intervention: Immunotherapy approaches including antibodies, peptides, or dendritic cell vaccines
Number of subjects: 0
Study: 11469160

Group type: EXPERIMENTAL
Intervention: Immediate debriefing (< 10 hr)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Delayed debriefing (> 48 hr)
Number of subjects: 77
Study: 9211625

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1 mg/kg s.c., bid and 1.5 mg/kg s.c. daily)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 17
Study: 8433421

Group type: EXPERIMENTAL
Intervention: Aspirin therapy (including enteric-coated aspirin and plain aspirin)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Aspirin therapy
Number of subjects: 444

Group type: COMPARATOR
Intervention: No aspirin
Number of subjects: 444
Study: 3310094

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 135

Group type: COMPARATOR
Intervention: CT
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: T1-weighted spin-echo (SE) pulse sequence
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Inversion-recovery (IR) pulse sequence
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: T2-weighted pulse sequences (TE 60 msec)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: T2-weighted pulse sequences (TE 120 msec)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Single T1-weighted (10-minute) pulse sequence
Number of subjects: 135
Study: 31664303

Group type: EXPERIMENTAL
Intervention: Piroxicam (200 mg)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 26731483

Group type: EXPERIMENTAL
Intervention: Octreotide LAR 30 mg
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Low tumor load subgroup (n=64)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: High tumor load subgroup (n=21)
Number of subjects: 85
Study: 25667217

Group type: EXPERIMENTAL
Intervention: Lidocaine 4% (0.2 mL)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Decongestant only
Number of subjects: 17
Study: 24967526

Group type: EXPERIMENTAL
Intervention: Adherence Estimator (AE) tool
Number of subjects: 388

Group type: EXPERIMENTAL
Intervention: Drug Adherence Work-up (DRAW) tool
Number of subjects: 388
Study: 21074608

Group type: EXPERIMENTAL
Intervention: (−)‐epicatechin (1.5mg/kg bw)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: (−)‐catechin (1.5mg/kg bw)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: +‐catechin (1.5mg/kg bw)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: +‐epicatechin (1.5mg/kg bw)
Number of subjects: 0
Study: 19523049

Group type: EXPERIMENTAL
Intervention: early-NIPPV
Number of subjects: 76

Group type: COMPARATOR
Intervention: early-CPAP
Number of subjects: 76
Study: 18162724

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patches
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 15554461

Group type: EXPERIMENTAL
Intervention: Hypnotherapeutic ego strengthening (HES) intervention pre- and postoperatively
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (non-intervention)
Number of subjects: 50
Study: 11681004

Group type: EXPERIMENTAL
Intervention: Postoperative adjuvant chemotherapy (combination therapy with mitomycin C, 5-fluorouracil, and nonspecific immunomodulators such as PSK and OK-432)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Biochemical modulators (low-dose FP and S 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Postoperative adjuvant chemotherapy
Number of subjects: 0
Study: 9716216

Group type: EXPERIMENTAL
Intervention: Cutting balloon angioplasty
Number of subjects: 0
Study: 7664193

Group type: EXPERIMENTAL
Intervention: Memory training (weekly group sessions of 60 min for 1 year)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreated control group
Number of subjects: 0
Study: 2718782

Group type: EXPERIMENTAL
Intervention: Calcium-25-OHD (1200 mg/day of calcium as calcium carbonate and 40 micrograms/day of 25-OHD)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Calcium-placebo (1200 mg/day of calcium plus placebo)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Calcium-25-OHD and Calcium-placebo
Number of subjects: 39
Study: 1097097

Group type: EXPERIMENTAL
Intervention: Daunorubicin (25 mg/m given intravenously) + Methotrexate (25 mg/m/dose given orally twice weekly)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Methotrexate (25 mg/m/dose given orally twice weekly)
Number of subjects: 63
Study: 30683167

Group type: EXPERIMENTAL
Intervention: Spiritual care using SpiPas and usual care
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 46
Study: 28619228

Group type: EXPERIMENTAL
Intervention: Lite intervention (8 community health club sessions)
Number of subjects: 8734

Group type: EXPERIMENTAL
Intervention: Classic intervention (20 community health club sessions)
Number of subjects: 8734

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 8734
Study: 25817614

Group type: EXPERIMENTAL
Intervention: Vertebrobasilar ectasia (VBE) present in 200 (7.6%) patients
Number of subjects: 2621
Study: 23702094

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (DHA and EPA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21375762

Group type: EXPERIMENTAL
Intervention: Chlorthalidone 12.5 mg plus amiloride 2.5 mg
Number of subjects: 1250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1250